Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid in primary biliary cholangitis
ISRCTN89514817Phase 3Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of obeticholic acid in primary biliary cholangitis (PBC) (4 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Safety and tolerability in cirrhosis and portal hypertension and Composite biochemical response. Started Jan 2012; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on ISRCTN89514817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89514817.